Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Search by expertise, name or affiliation
Apixaban, an oral, direct inhibitor of activated Factor Xa
Eduard Shantsila
,
Gregory Lip
Cardiovascular Sciences
Research output
:
Contribution to journal
›
Article
45
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Apixaban, an oral, direct inhibitor of activated Factor Xa'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Factor Xa
100%
Direct Inhibitors
100%
Apixaban
100%
Pfizer
33%
Coronary Artery Disease
33%
Phase III Clinical Trial
33%
Deep Vein Thrombosis
33%
Phase II Clinical Trial
33%
Cerebrovascular Ischemia
33%
Bristol-Myers Squibb
33%
Lung Embolism
33%
Oral Direct Factor Xa Inhibitor
33%
Pharmacology, Toxicology and Pharmaceutical Science
Blood Clotting Factor 10a
100%
Apixaban
100%
Clinical Trial
66%
Brain Ischemia
33%
Coronary Artery Disease
33%
Deep Vein Thrombosis
33%
Lung Embolism
33%
Blood Clotting Factor 10a Inhibitor
33%
Medicine and Dentistry
Apixaban
100%
Prothrombinase
100%
Clinical Trial
66%
Coronary Artery Disease
33%
Pulmonary Embolism
33%
Brain Ischemia
33%
Deep Vein Thrombosis
33%
Blood Clotting Factor 10a Inhibitor
33%